Provided by Tiger Trade Technology Pte. Ltd.

Relmada Therapeutics, Inc.

4.07
-0.0200-0.49%
Pre-market: 4.520.4499+11.05%07:59 EDT
Volume:2.81M
Turnover:11.41M
Market Cap:435.49M
PE:-4.38
High:4.25
Open:4.25
Low:4.00
Close:4.09
52wk High:8.00
52wk Low:1.45
Shares:107.00M
Float Shares:78.16M
Volume Ratio:2.26
T/O Rate:3.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9300
EPS(LYR):-1.4535
ROE:-55.66%
ROA:-32.39%
PB:2.11
PE(LYR):-2.80

Loading ...

Relmada Therapeutics raises authorized common shares to 200 million from 150 million

Reuters
·
May 29

Relmada Therapeutics - Increases Authorized Common Stock to 200 Mln Shares From 150 Mln - SEC Filing

THOMSON REUTERS
·
May 29

BRIEF-Relmada Therapeutics Inc Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing

Reuters
·
May 14

Relmada Therapeutics Inc: Files for Mixed Shelf Offering, Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
May 14

Piper Sandler Sticks to Its Buy Rating for Relmada Therapeutics (RLMD)

TIPRANKS
·
May 13

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 13

Relmada Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Relmada Therapeutics Q1 Loss per Share Narrows

MT Newswires Live
·
May 13

Earnings Flash (RLMD) Relmada Therapeutics Posts Q1 Loss $0.22, vs. FactSet Est of $0.20 Loss

MT Newswires Live
·
May 13

Relmada Q1 FY26 net loss widens to $19.1 million; R&D expense falls to $8.1 million

Reuters
·
May 13

Relmada Therapeutics Q1 EPS USD -0.22

THOMSON REUTERS
·
May 13

Relmada Therapeutics Inc - on Track to Initiate Phase 3 Rescue Program in Nmibc in Mid-2026

THOMSON REUTERS
·
May 13

Corrected-Relmada Therapeutics Q1 Cash & Investments USD 234 Million (Corrects Amount)

THOMSON REUTERS
·
May 13

Press Release: Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 13

Relmada Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
May 09

Relmada Therapeutics schedules first-quarter 2026 results conference call and webcast

Reuters
·
May 06

Relmada to launch Phase 3 RESCUE trial of NDV-01 in mid-2026

Reuters
·
May 05

Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)

TIPRANKS
·
Apr 08

Relmada Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 07

PreveCeutical appoints Dr. Raj S. Pruthi to board of directors

Reuters
·
Mar 30